Your Health, We Care
Release date: 2026-05-12 15:24:30 Recommended: 7
Palbociclib 125 mg capsules and tablets are indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in adult patients. The drug must be used in combination with the following agents: with an aromatase inhibitor as initial endocrine-based therapy; or with fulvestrant in patients with disease progression following endocrine therapy. This combination strategy provides an important treatment option for HR+/HER2- metastatic breast cancer.
Neutropenia was the most common adverse reaction in clinical trials of palbociclib. In the PALOMA-2 study, the incidence in the palbociclib plus letrozole group was 80% (Grade 3: 56%, Grade 4: 10%); in the PALOMA-3 study, the incidence in the palbociclib plus fulvestrant group was 83% (Grade 3: 55%, Grade 4: 11%). In addition, febrile neutropenia was reported in 1.8% of patients, and one death due to neutropenic sepsis occurred in the PALOMA-3 study. Therefore, patients should promptly report any fever. Complete blood count must be monitored before treatment, at the beginning of each cycle, on day 15 of the first two cycles, and as clinically indicated. For patients developing Grade 3 or 4 neutropenia, dose interruption, dose reduction, or delay in starting the next cycle is recommended.
Patients treated with CDK4/6 inhibitors (including palbociclib in combination with endocrine therapy) may experience severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis. In the PALOMA-1, PALOMA-2, and PALOMA-3 clinical trials, any-grade ILD/pneumonitis was reported in 1% of patients receiving palbociclib, with Grade 3 or 4 occurring in 0.1% of patients; no deaths were reported. However, additional cases and deaths have been observed post-marketing. Physicians should monitor patients for pulmonary symptoms suggestive of ILD/pneumonitis, such as hypoxia, cough, and dyspnea. For patients with suspected pneumonitis, palbociclib should be interrupted immediately and the patient should be evaluated. Patients diagnosed with severe ILD or pneumonitis require permanent discontinuation of the drug.
